Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis

Who May Qualify: - \- Male or female at least 18 years of age - \- A diagnosis of ESKD undergoing maintenance dialysis for at least 12 weeks - \- Serum hs-CRP ≥ 2.0 mg/L - \- A diagnosis of diabetes mellitus OR ASCVD Who Should NOT Join This Trial: - \- Subjects who participated in Part 1 (phase 2b) are not eligible to participate in Part 2 (phase 3) - \- Concomitant use of systemic immunosuppressant drugs - \- Abnormal LFTs - \- Any life-threatening disease expected to result in death within 12 months - \- A history of GI perforation, inflammatory bowel disease (except fully excised ulcerative colitis), or peptic ulcer disease - -Clinically significant active infection or history of opportunistic or invasive fungal infection Always talk to your doctor about whether this trial is right for you.